Popular Articles

What Is The Relationship Between Hepatocellular Carcinoma And Type 2 Diabetes Mellitus?
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related deaths. Type 2 diabetes mellitus has been associated with HCC. However, the relationship between type 2 diabetes mellitus and the underlying liver cirrhosis, and the effects of antidiabetic therapy on HCC risk have not yet been fully evaluated.

Strategies For Lower Extremity PAD Compared
Lower extremity peripheral arterial disease (PAD) affects more than eight million Americans, with significant risks of limb loss, disability and death. Treatment of lower extremity PAD focuses on restoring normal blood supply to the affected limb. Traditional treatment, such as surgical bypass, is effective but invasive. In recent years, many patients have been treated with newer endovascular interventions, using catheter-based devices to reopen peripheral arteries in a less-invasive fashion. According to past research, it is unclear if these newer treatments are as effective as conventional surgical bypass in preventing amputation.
News of the day
Janet Rowley Receives Presidential Medal Of Freedom For Cancer Chromosome Studies In Leukemias And Lymphomas
Janet Davison Rowley, MD, a pioneer in demonstrating that cancer is a genetic disease, will receive the 2009 Presidential Medal of Freedom the White House announced Thursday. President Barack Obama will award the Medals of Freedom, the nation"s highest civilian honor, to Rowley and 15 others at a ceremony Wednesday, August 12.
Diagnostics

Typhoid Vaccine Effectively Prevents Disease In Children, Study Finds

"A typhoid vaccine proved effective in the slums of India, where it not only helped prevent infection in children who received it, but also those in close contact who were unvaccinated," according to a New England Journal of Medicine study published on Thursday, the AP/Washington Post reports (Chang, 7/22). The study, "conducted in two wards of an Indian slum where about 60,000 people live," sought to investigate the Vi typhoid vaccine"s efficacy in children between the ages of 2 and 5, Reuters writes. "Doubt about its effectiveness in this younger age group is one reason the shots, which cost as little as 50 cents, are not widely given to prevent typhoid. The potentially deadly disease comes from contaminated food and water, and kills 216,000 to 600,000 people worldwide each year," according to the news service (Emery, 7/22). Researchers found that the vaccine was 80 percent effective in preventing typhoid fever among the children in the study. The vaccine also offered 44 percent protection among "unvaccinated neighbors who were in contact with the immunized children," according to the AP/Washington Post. "Overall, the vaccine was 61 percent effective," the newspaper reports. Though typhoid fever is treatable with antibiotics, new drug-resistant strains have arisen (7/22). In addition, "Safe and effective vaccines exist but are used mainly by wealthy travellers to developing countries rather than by poor residents," AFP/Google.com writes (7/23). According to the AP/Washington Post, the study was funded by the Bill and Melinda Gates Foundation and coordinated by the International Vaccine Institute (IVI). GlaxoSmithKline donated the vaccine used in the research (7/22). In an IVI statement, IVI Director-General John Clemens said, "The protection for children under the age of five years is important because this age group has been shown to be at high risk for typhoid fever in many areas where the disease is endemic" (7/22). In a related NEJM commentary, Myron Levine of the University of Maryland School of Medicine wrote, "The time has come to implement use of these vaccines vigorously and monitor the effect of such intervention," according to Reuters (7/22). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):